MAIA · MAIA Biotechnology, Inc. · Financials
Market Cap
$79.07M
Shares
60.83M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2024
Net Income
-$22.4M
+3.7%
FY2025
Diluted EPS
-$0.70
+33.3%
FY2025
Operating Cash Flow
-$18.84M
-20%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | $0 | $0 | $0 | — | |
| -$171.34K | $453.75K | $10.01M | $11.11M | $8.93M | $3.5M | |
| $11.54M | $9.72M | $6.95M | $9.07M | $6.14M | $4.29M | |
| $28.95M | $24.27M | $16.96M | $20.18M | $16.18M | $7.79M | |
| -$28.95M | -$24.27M | -$16.96M | -$20.18M | -$16.18M | -$7.79M | |
| — | — | $57 | $6863 | $6967 | $827.54K | |
| $347.75K | — | $318.37K | $34.49K | $1870 | $2012 | |
| — | -$22.39M | -$23.25M | -$19.8M | -$15.8M | -$12.6M | |
| $2339 | $2000 | $2000 | — | — | — | |
| -$26.85M | -$22.4M | -$23.25M | -$19.77M | -$15.77M | -$12.58M | |
| — | — | — | — | — | -$74.33K | |
| -$26.85M | -$22.4M | -$23.25M | -$19.77M | -$16.22M | -$12.5M | |
| -$26.86M | -$22.42M | -$23.27M | -$19.77M | -$16.24M | -$12.5M | |
| USD/shares | -$0.63 | -$0.70 | -$1.05 | -$1.49 | -$1.75 | -$2.37 |
| USD/shares | -$0.63 | -$0.70 | -$1.05 | -$1.49 | -$1.75 | -$2.37 |
| shares | — | 32.11M | 22.2M | 13.26M | 9.28M | 5.28M |
| shares | — | 32.11M | 22.2M | 13.26M | 9.28M | 5.28M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.49×
EV/EBIT
—
Peer median 12.38×
P/E (TTM)
—
Peer median 8.07×
Peer medians compare against the 300 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1878313
CUSIP
552641102
13F (30d)
12 filings
12 filers
Visit website
Investor relations